<DOC>
	<DOCNO>NCT02069197</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ketogenic diet ( KD ) treatment ( ) obesity , ( ii ) type 2 diabetes mellitus ( iii ) obstructive sleep apnea ( OSA ) patient obesity Type 2 DM patient obesity and/or OSA . This randomized , open-label three arm control study compare weight loss obese participant type 2 diabetes and/or obstructive sleep apnea treat 9 month 3:1 [ fat ] : [ protein+carbohydrate ] ratio , 1600 kcal/day diet ( Group A ) weight loss participant treat orlistat 120 mg TID lifestyle intervention consist dietary advice , recommend caloric goal 1600 kcal/day ( Group B ) , participant treat lifestyle intervention consist dietary advice , recommend caloric goal 1600 kcal/day ( Group C ) .</brief_summary>
	<brief_title>Ketogenic Diet Treatment Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea</brief_title>
	<detailed_description>The study sample randomize three treatment arm , KD ( Group A , n=50 ) , Orlistat 120 mg TID ( Group B , n=50 ) dietary lifestyle counseling ( Group C , n=50 ) 1:1:1 ratio . Each arm include 100 % participant obesity co-morbid type 2 DM 50 % participant co-morbid OSA . Randomization stratify diabetic status .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>age 1870 ability willingness sign informed consent form BMI 30kg/m2 , type 2 DM and/or OSA For diabetic participant , stable hypoglycemic medication least 2 month For participant OSA , previously document polysomnogram apnea/hypopnea index ( AHI ) &gt; 15/h . BMI change +/ 3.0 kg/m2 baseline BMI within past 12 month . History bariatric surgery â‰¤ 3 year prior enrollment . Any systemic illness unstable medical condition might pose additional risk , include : cardiac , unstable metabolic endocrine disturbance , renal liver disease , past history renal calculus , hyperuricemia , hypercalcemia , mitochondrial disease , know disorder fatty acid metabolism , porphyria , active systemic cancer . History uncontrolled hyperlipidemia For participant DM , change dose type hypoglycemic treatment within 2 month prior enrollment . Psychosis within six month enrollment , evidence treatment antipsychotic medication recent medication initiation dose increase . Active drug alcohol dependence factor , opinion site investigator would interfere adherence study requirement ; History hyperthyroidism History glaucoma History cerebrovascular disease unstable heart disease within 6 month enrollment Pregnancy Use investigational drug within 3 month enrollment . Inability unwillingness subject give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ketogenic diet</keyword>
	<keyword>obesity</keyword>
	<keyword>diabetes</keyword>
	<keyword>obstructive sleep apnea</keyword>
</DOC>